AstraZeneca’s LATIFY Trial Misses Primary Endpoint in Previously Treated Advanced NSCLC

As reported on PharmaBiz, AstraZeneca’s phase III LATIFY trial has fallen short of its primary objective, with the combination of the ATR inhibitor ceralasertib and the PD‑L1 inhibitor Imfinzi (durvalumab)…

Continue Reading AstraZeneca’s LATIFY Trial Misses Primary Endpoint in Previously Treated Advanced NSCLC

Oligodendrocyte‑Targeted Gene Therapy Shows Breakthrough Potential in Canavan Disease

As reported on InsidePrecisionMedicine, a new gene therapy aimed directly at the cells responsible for myelination is showing unprecedented promise for children with Canavan disease, a rare and fatal leukodystrophy.…

Continue Reading Oligodendrocyte‑Targeted Gene Therapy Shows Breakthrough Potential in Canavan Disease

Hidden Protein Markers Offer New Hope for Predicting Prostate Cancer Across Diverse Communities

Prostate cancer doesn't affect all men equally. Medical researchers have long known that men with African ancestry experience significantly higher rates and more severe outcomes than other groups. Now, according…

Continue Reading Hidden Protein Markers Offer New Hope for Predicting Prostate Cancer Across Diverse Communities